Home Amaranth Medical, Inc

Amaranth Medical, Inc

Amaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCT

9/25/18: Antonio Colombo, MD, director of the Hemodynamics Division at Ospedale San Raffaele in Milan, Italy and co-principal investigator of the RENASCENT studies, presented nine-month follow-up results of the 70 patients implanted with MAGNITUDE®, the company’s 98-micron BRS. Dr. Colombo noted, “At nine months, MAGNITUDE continues to perform clinically well and it sets a new standard for thin-strutted scaffold performance. The MAGNITUDE BRS displays similar mechanical performance compared to metallic drug-eluting stent (DES) not requiring changes in the implantation technique. We are approaching a new phase in the investigation of this device with plans to conduct a larger head-to-head comparative study against metallic DES.”